IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 628
- Registration Number
- NCT02853409
- Locations
- 🇪🇸
Hospital Quirón Campo de Gibraltar, Cádiz, Spain
🇪🇸H. San Juan de Dios, Córdoba, Spain
🇪🇸H. Can Misses, Ibiza, Spain
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
- Conditions
- Acromegaly
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 115
- Registration Number
- NCT02807233
- Locations
- 🇪🇸
Hospital Univ. Príncipe de Asturias, Alcalá de Henares, Spain
🇪🇸Hospital Univ. Nuestra Sra. Candelaria, Santa Cruz, Tenerife, Spain
🇪🇸Complejo Hospitalario Univ. A Coruña, A Coruña, Spain
A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
- Conditions
- Neuroendocrine Tumours
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT02788578
- Locations
- 🇫🇷
IUCT Oncopole, Toulouse, France
🇮🇹Unversità degli Studi di Messina, Messina, Italy
🇩🇪Zentralklinil Bad Berka, Bad Berka, Germany
Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumours
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 156
- Registration Number
- NCT02788565
- Locations
- 🇸🇪
Skane University Hospital, Lund, Sweden
🇸🇪Uppsala University Hospital, Uppsala, Sweden
Community-based Neuroendocrine Tumor (NET) Research Study
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 100
- Registration Number
- NCT02730104
- Locations
- 🇺🇸
Texas Oncology - Denton South, Denton, Texas, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Illinois Cancer Specialists, Arlington Heights, Illinois, United States
Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 858
- Registration Number
- NCT02704091
- Locations
- 🇩🇿
CHU BEN BADIS Constantine, Constantine, Algeria
🇹🇳CSB Zouhour, Sousse, Tunisia
🇪🇬Cairo University, Cairo, Egypt
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
- Conditions
- Neuroendocrine Tumours
- Interventions
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2020-10-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT02698410
- Locations
- 🇮🇹
Oncologia Medica - Istituto Tumori Regina Elena San Gallicano, Roma, Italy
🇮🇹Oncologia Medica - Istituto Oncologico del Mediterraneo - IOM, Viagrande, Catania, Italy
🇮🇹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l., IRCCS, Meldola, Italy
Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
- Conditions
- Acromegaly
- First Posted Date
- 2016-03-03
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 4
- Registration Number
- NCT02698384
- Locations
- 🇫🇷
Hopital Larrey, Toulouse, France
🇫🇷Hoptial Nord, Amiens, France
🇫🇷Hopital Albert Michallon, La Tronche, France
Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 24
- Registration Number
- NCT02683577
- Locations
- 🇷🇴
ARENSIA Exploratory Medicine, Bucharest, Romania
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
- Conditions
- Neuroendocrine Tumors in Lung
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 77
- Registration Number
- NCT02683941
- Locations
- 🇺🇸
Roswell Park Cancer Center, Buffalo, New York, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇫🇷CHU de Rennes - Hôpital Pontchaillou, Rennes, France